Last updated 9 days ago
A Safety and Efficacy Study of GTX-102 in Subjects With Deletion- or Nondeletion-type Angelman Syndrome (AS)
60 patients around the world
Available in Argentina, United States, Brazil
This basket study is designed to evaluate safety and efficacy of GTX-102 in participants
with Angelman syndrome across genotypes and age groups. The study consists of
subprotocols A, B, C and D. All subprotocols are open-label and follow the same design
which includes a Screening, Loading and Maintenance period. Subprotocols A, B and C are
single arm only. In subprotocol D, participants are randomized 2:1 to a GTX-102 group or
a No Treatment group. The No Treatment group follows the same schedule of events as all
other groups after completion of the No Treatment period. Participants from all the
subprotocols have the option to continue treatment in a long-term extension study
following their end of study visit.
Ultragenyx Pharmaceutical Inc
60Patients around the world
This study is for people with
Rare diseases
Angelman syndrome
Requirements for the patient
To 64 Years
All Gender
Medical requirements
- Signed informed consent from parent(s) or legal guardian(s).Males and females of the following ages and genotypes at time of informed consent.Subprotocol A: ≥ 1 to < 4 years of age with a genetically confirmed diagnosis of deletion-type Angelman syndrome.Subprotocol B: ≥ 4 to < 18 years of age with a genetically confirmed diagnosis of UPD/ICD Angelman syndrome.Subprotocol C: ≥ 18 to < 65 years of age with a genetically confirmed diagnosis of Angelman syndrome, any genotype.Subprotocol D: ≥ 4 to < 18 years of age with a genetically confirmed diagnosis of mutation-type Angelman syndrome.Weight ≥ 8 kg at Screening Visit.Platelet count, prothrombin time / international normalized ratio, and partial thromboplastin time < 1.5x the upper limit of normal and platelets > 75,000 cells/mm3 at the Screening Visit.Willing and able to comply with scheduled visits, drug administration plan, laboratory tests, and all study procedures, including lumbar puncture (LP) procedure, magnetic resonance imaging (MRI) and tolerating anesthesia without intubation.From the time of informed consent through to at least 6 months after the final dose of GTX-102, females of childbearing potential who are sexually active must use highly effective contraception or abstinence.Males are able to participate if they agree to remain abstinent (refrain from heterosexual intercourse) or use acceptable contraceptive methods during the study and for at least 3 months after the final dose of GTX-102.
- Any change in medications or diet/supplements intended to treat symptoms of Angelman Syndrome (eg, sleeping aids, antiseizure medications, supplements, dietary change including ketogenic or low-glycemic index diet, other) within the month prior to the Screening Visit (excluding weight-based adjustments).Any condition that creates an increased risk of unsuccessful lumbar puncture.Current or expected concomitant use of drugs that increase the risk of bleeding (eg, heparin, low molecular weight heparin, platelet inhibitors).Known hypersensitivity to GTX-102 or its excipients or required premedication that, in the judgment of the Investigator, places the subject at increased risk for adverse effects.Presence or history of any condition, lab abnormality, or infection that, in the judgment of the Investigator, would interfere with study participation, pose undue safety risk, or would confound interpretation of results.Pregnant or breastfeeding or planning to become pregnant (self or partner) at any time during the study.Use of any investigational product or investigational medical device within 6 months or 5 half-lives prior to the Screening Visit, or any prior use of gene therapy or an ASO regardless of length of time since last use.Concurrent participation in any interventional study.
StudyAurora
SponsorUltragenyx Pharmaceutical Inc
Study typeInterventional
Conditions
Angelman syndrome
Requirements
To 64 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT07157254
